IOVA

Iovance Biotherapeutics Inc. (IOVA) | Rumor.io

Iovance Biotherapeutics

IOVA

Attention (50-day avg)0.13%

Attention rank (50-day avg)#83

Bullish sentiment (50-day avg)89%

Price to earnings ratio-10.1

Market capitalization5B

Earnings per share-0.69

Dividend yield (TTM)—

Revenue (annual)263.5M

Net income (annual)-391M

Social

What share of all stock conversation is about IOVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	1.03% +0.91	0.26% +0.07	0.14% +0.05	0.03% -0.03

Sep 30

The author is holding a significant amount of IOVA shares, believing it to be a long-term winner that could change the narrative for their family for generations to come.
IOVA's recent volume and institutional buying activity are encouraging, with a strong bull candle breaking above all short-term moving averages and a closing price more than 30% above both the 20-day and 50-day moving averages.
The company's Global NSCLC Commercial Opportunity is significant, with a potential 7X current melanoma opportunity, and the FDA has granted Fast Track Designation in second-line nonsquamous mNSCLC.

Generated by AI

Sentiment

Of the messages about IOVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90.2% -8.99	91.48% +5.08	89.96% +2.19	83.96% +8.19
Bearish	9.8% +8.99	8.52% -5.08	10.04% -2.19	16.04% -8.19

Bullish· Sep 30

The company's revenue projections are expected to be exceeded, with some analysts predicting $1.4 billion in revenue for calendar 2027 and $2 billion in 2028.
The stock has been accumulating institutional buying, with a massive 78 million shares traded in a single day, indicating deep investor interest and a strong upward momentum.
The company's clinical pipeline is expected to deliver significant results, with the potential for a SP of $100+ in the long term, driven by the upcoming release of data from the lung trial and other clinical data.

Bearish· Sep 29

The sentiment among the community is overwhelmingly bearish, with many users advising others to sell their shares of IOVA, citing the stock's potential for further decline.
Several users express frustration with the short-sellers, accusing them of manipulating the market and creating a "bad infestation" on the forum.
The stock's potential for significant growth is dismissed by some users, with one user stating that the stock will be trading at $20+ per share only in 2027-2028, and another user predicting that the stock will be worthless by Q3 2028.

Generated by AI

Topics

Of the messages about IOVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	19.34%	30.57%	36.58%	23.83%
Technical Analysis	24.61%	18.31%	4.43%	11.42%
Announcements	27.93%	23.32%	8.88%	24.66%
Earnings	28.13%	24.29%	16%	15.07%
Macro	0%	3.5%	34.1%	24.58%
Controversies	0%	0%	0.01%	0.45%

Earnings· Sep 29

Iovance Biotherapeutics raises FY26 revenue view to $410M-$420M, up from $350M-$370M, driven by strong U.S. demand for Amtagvi and Proleukin, and manufacturing schedule visibility into Q3 and Q4.
The company's record second-quarter 2026 total product revenue was $99.3 million, and it expects to report third-quarter 2026 financial results in early November 2026.
Iovance's guidance raise implies nearly 60% annual growth, and the company's stock price has increased by over 25% to its highest level in over two years, with analysts likely to revise their forward revenue and profit guidance upwards.

Analysts· Sep 24

Goldman Sachs resumed coverage of Iovance Biotherapeutics with a Buy rating and $15 price target, citing an inflection in the company's Amtagvi launch and improved gross margins.
The analyst sees easing operational and logistical constraints regarding the commercial rollout of Amtagvi, positioning the company for long-term profitability and long-term profitability in 2028.
Goldman Sachs' upgrade from a $2 Sell to a $15 Buy is a significant shift in confidence around Amtagvi, improving margins, and the upside from the IOV-LUN-202 trial, which could help bring more institutional attention to the stock.

Announcements· Sep 29

Iovance Biotherapeutics, Inc. (IOVA) raised its FY26 total revenue guidance to $410-$420M, citing strong U.S. demand for Amtagvi and Proleukin.
Analysts are optimistic about IOVA's future, with one analyst raising the price target to $20 and maintaining a Buy rating.
IOVA has a strong manufacturing process and ATC network, positioning it for success in the market, and could potentially be a buyout target for big pharma companies.

Controversies· Dec 27

The FDA placed a clinical hold on Iovance's IOV-LUN-202 trial due to a Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
The clinical hold is independent of the FDA's Priority Review of the biologics license application (BLA) for lifileucel in advanced melanoma, and has no impact on other Iovance clinical trials.
Iovance's stock price fell by as much as 28% in premarket trading after the FDA announcement, with some analysts defending the company's shares as a potential buying opportunity.

Technical Analysis· Sep 29

The stock has formed a base at $14.90, and the MACD is ready to curl up, with the RSI already oversold on the 1-minute chart, indicating a potential next leg up.
The stock is forming higher lows and higher highs, a nice pattern that suggests it's trending upwards, with the author expecting a potential acquisition by a larger pharmaceutical company.
The author believes recent price action, volume structure, and upcoming catalysts are more relevant than traditional technical analysis, which is affected by the significant change in share count due to dilution, making old support/resistance levels less relevant.

Generated by AI

Community

Of the messages about IOVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	81.89%	85.34%	90.08%	82.77%
Newcomers	18.11%	14.66%	9.92%	17.23%

Regulars· Sep 30

$IOVA has been steadily increasing in value, with the stock price reaching $15 and showing no signs of slowing down, despite some investors expecting a 20-40% pullback.
The company's revenue guidance has been revised to $410-$420 million, with some analysts predicting it could reach $640 million in 2027, driven by improving margins and the potential for new revenue streams.
The stock's recent surge is likely to continue, with the company's clinical pipeline delivering anticipated results, including data from the lung trial and potential indications, and the FDA's Fast Track Designation in Second-Line Nonsquamous mNSCLC.

Newcomers· Sep 29

Newcomers to the IOVA stock are focused on its rapid price increase, with one user mentioning a $4 million upswing in a single day.
Many new investors are impressed by IOVA's recent guidance raise to $410-$420 million, representing nearly 60% annual revenue growth, and are optimistic about its commercial momentum.
Some newcomers are excited about the potential for a short squeeze, with one user predicting that IOVA's price could reach $20, and others are speculating about a possible buyout or takeover.

Generated by AI

Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

2h agoYahoo Finance

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence.

10h agoYahoo Finance

Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why T

FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.

11h agoBenzinga

Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%

Iovance Biotherapeutics (NASDAQ:IOVA) saw its share price increase by 31.48 percent on Tuesday to finish at $14.45 apiece after raising its full-year revenue growth guidance by as much as 60 percent, thanks to the strong demand for its cancer treatments. In an updated report on the same day, the company said that it is now […]

12h agoYahoo Finance

Iovance: The Turnaround Is Priced In, Downgrading To Hold (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. stock surges as AMTAGVI launch beats expectations; FY26 guidance raised. Click here to read this IOVA update.

16h agoSeeking Alpha

Iovance stock rises as analysts cheer new outlook (IOVA:NASDAQ)

Iovance Biotherapeutics (IOVA) stock jumps as the company raises its full-year revenue to a level above the consensus, implying nearly 60% YoY growth. Read more here.

18h agoSeeking Alpha

Also Discussed

Investors talking about IOVA also mention

#	Name	Attention
1	Replimune Group, Inc.REPL	0%0
2	Aquestive Therapeutics Inc.AQST	0%+0
3	ImmunityBio Inc.IBRX	0.28%-0.07
4	DAWN - Day One Biopharmaceuticals, Inc.	——
5	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	TG Therapeutics Inc.TGTX	0.01%+0
8	Instil Bio Inc.TIL	0%0
9	Ars Pharmaceuticals IncSPRY	0%0
10	Viking Therapeutics, Inc.VKTX	0.18%0

Iovance Biotherapeutics Inc.

Healthcare
Biotechnology

Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell therapy used in advanced melanoma, and Proleukin, which supports the treatment regimen. The company also advances investigational TIL-based programs for other solid tumors, including cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma. Iovance Biotherapeutics operates as an oncology-focused cell therapy platform, combining manufacturing, clinical development, and commercialization capabilities to deliver personalized immunotherapies for patients with difficult-to-treat cancers. Headquartered in San Carlos, California, it plays a specialized role in the broader biopharmaceutical market by bringing autologous immune-cell therapies into routine clinical use.

Website

Location

825 Industrial Road

San Carlos, CA, 94070

United States

Social

What share of all stock conversation is about IOVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	1.03% +0.91	0.26% +0.07	0.14% +0.05	0.03% -0.03

Sep 30

The author is holding a significant amount of IOVA shares, believing it to be a long-term winner that could change the narrative for their family for generations to come.
IOVA's recent volume and institutional buying activity are encouraging, with a strong bull candle breaking above all short-term moving averages and a closing price more than 30% above both the 20-day and 50-day moving averages.
The company's Global NSCLC Commercial Opportunity is significant, with a potential 7X current melanoma opportunity, and the FDA has granted Fast Track Designation in second-line nonsquamous mNSCLC.

Generated by AI

Sentiment

Of the messages about IOVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90.2% -8.99	91.48% +5.08	89.96% +2.19	83.96% +8.19
Bearish	9.8% +8.99	8.52% -5.08	10.04% -2.19	16.04% -8.19

Bullish· Sep 30

The company's revenue projections are expected to be exceeded, with some analysts predicting $1.4 billion in revenue for calendar 2027 and $2 billion in 2028.
The stock has been accumulating institutional buying, with a massive 78 million shares traded in a single day, indicating deep investor interest and a strong upward momentum.
The company's clinical pipeline is expected to deliver significant results, with the potential for a SP of $100+ in the long term, driven by the upcoming release of data from the lung trial and other clinical data.

Bearish· Sep 29

The sentiment among the community is overwhelmingly bearish, with many users advising others to sell their shares of IOVA, citing the stock's potential for further decline.
Several users express frustration with the short-sellers, accusing them of manipulating the market and creating a "bad infestation" on the forum.
The stock's potential for significant growth is dismissed by some users, with one user stating that the stock will be trading at $20+ per share only in 2027-2028, and another user predicting that the stock will be worthless by Q3 2028.

Generated by AI

Topics

Of the messages about IOVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	19.34%	30.57%	36.58%	23.83%
Technical Analysis	24.61%	18.31%	4.43%	11.42%
Announcements	27.93%	23.32%	8.88%	24.66%
Earnings	28.13%	24.29%	16%	15.07%
Macro	0%	3.5%	34.1%	24.58%
Controversies	0%	0%	0.01%	0.45%

Earnings· Sep 29

Iovance Biotherapeutics raises FY26 revenue view to $410M-$420M, up from $350M-$370M, driven by strong U.S. demand for Amtagvi and Proleukin, and manufacturing schedule visibility into Q3 and Q4.
The company's record second-quarter 2026 total product revenue was $99.3 million, and it expects to report third-quarter 2026 financial results in early November 2026.
Iovance's guidance raise implies nearly 60% annual growth, and the company's stock price has increased by over 25% to its highest level in over two years, with analysts likely to revise their forward revenue and profit guidance upwards.

Analysts· Sep 24

Goldman Sachs resumed coverage of Iovance Biotherapeutics with a Buy rating and $15 price target, citing an inflection in the company's Amtagvi launch and improved gross margins.
The analyst sees easing operational and logistical constraints regarding the commercial rollout of Amtagvi, positioning the company for long-term profitability and long-term profitability in 2028.
Goldman Sachs' upgrade from a $2 Sell to a $15 Buy is a significant shift in confidence around Amtagvi, improving margins, and the upside from the IOV-LUN-202 trial, which could help bring more institutional attention to the stock.

Announcements· Sep 29

Iovance Biotherapeutics, Inc. (IOVA) raised its FY26 total revenue guidance to $410-$420M, citing strong U.S. demand for Amtagvi and Proleukin.
Analysts are optimistic about IOVA's future, with one analyst raising the price target to $20 and maintaining a Buy rating.
IOVA has a strong manufacturing process and ATC network, positioning it for success in the market, and could potentially be a buyout target for big pharma companies.

Controversies· Dec 27

The FDA placed a clinical hold on Iovance's IOV-LUN-202 trial due to a Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
The clinical hold is independent of the FDA's Priority Review of the biologics license application (BLA) for lifileucel in advanced melanoma, and has no impact on other Iovance clinical trials.
Iovance's stock price fell by as much as 28% in premarket trading after the FDA announcement, with some analysts defending the company's shares as a potential buying opportunity.

Technical Analysis· Sep 29

The stock has formed a base at $14.90, and the MACD is ready to curl up, with the RSI already oversold on the 1-minute chart, indicating a potential next leg up.
The stock is forming higher lows and higher highs, a nice pattern that suggests it's trending upwards, with the author expecting a potential acquisition by a larger pharmaceutical company.
The author believes recent price action, volume structure, and upcoming catalysts are more relevant than traditional technical analysis, which is affected by the significant change in share count due to dilution, making old support/resistance levels less relevant.

Generated by AI

Community

Of the messages about IOVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	81.89%	85.34%	90.08%	82.77%
Newcomers	18.11%	14.66%	9.92%	17.23%

Regulars· Sep 30

$IOVA has been steadily increasing in value, with the stock price reaching $15 and showing no signs of slowing down, despite some investors expecting a 20-40% pullback.
The company's revenue guidance has been revised to $410-$420 million, with some analysts predicting it could reach $640 million in 2027, driven by improving margins and the potential for new revenue streams.
The stock's recent surge is likely to continue, with the company's clinical pipeline delivering anticipated results, including data from the lung trial and potential indications, and the FDA's Fast Track Designation in Second-Line Nonsquamous mNSCLC.

Newcomers· Sep 29

Newcomers to the IOVA stock are focused on its rapid price increase, with one user mentioning a $4 million upswing in a single day.
Many new investors are impressed by IOVA's recent guidance raise to $410-$420 million, representing nearly 60% annual revenue growth, and are optimistic about its commercial momentum.
Some newcomers are excited about the potential for a short squeeze, with one user predicting that IOVA's price could reach $20, and others are speculating about a possible buyout or takeover.

Generated by AI

Iovance Biotherapeutics

Social

Sep 30

Bullish· Sep 30

Bearish· Sep 29

Earnings· Sep 29

Analysts· Sep 24

Announcements· Sep 29

Controversies· Dec 27

Technical Analysis· Sep 29

Regulars· Sep 30

Newcomers· Sep 29

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why T

Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%

Iovance: The Turnaround Is Priced In, Downgrading To Hold (NASDAQ:IOVA)

Iovance stock rises as analysts cheer new outlook (IOVA:NASDAQ)

Also Discussed

Iovance Biotherapeutics Inc.

Company Information

Location

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why T

Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%

Iovance: The Turnaround Is Priced In, Downgrading To Hold (NASDAQ:IOVA)

Iovance stock rises as analysts cheer new outlook (IOVA:NASDAQ)

Also Discussed

Social

Sep 30

Bullish· Sep 30

Bearish· Sep 29

Earnings· Sep 29

Analysts· Sep 24

Announcements· Sep 29

Controversies· Dec 27

Technical Analysis· Sep 29

Regulars· Sep 30

Newcomers· Sep 29